Agenda

I aim to elucidate how these innovative developments are poised to transform Pharma Research & Development, offering a deep dive into the concept of a ‘Bioatomspace.’ This segment will demonstrate the application of AI in studying human longevity, focusing on the integration of diverse model organism data within these AI frameworks. A core thesis of my presentation is the pivotal role of contemporary AI breakthroughs in reshaping the R&D arena. I will argue that entities not embracing this technological evolution risk obsolescence, underscoring the imperative for immediate and strategic adaptation in the face of this paradigm shift.

In today’s complex healthcare ecosystem when the local regulatory authorities have numerous nuances, it is important to think beyond the regulatory and clinical trial perspective to improve a product’s probability of success in the global markets. Investing in product planning at very early stages has earned greater prominence in recent years. Through this session, we would like to share Molekule Consulting’s perspectives on the key factors to success to win the global markets.

1. Advance your understanding of core regulatory routes, timelines and strategies
2. Understand core Gx/biosimilar product development and entry strategies
3. Learn from & set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
The presentation will be supported by thought provoking real-world case studies to stress differences between theory vs actual approaches

By examining various approaches, including studying the accuracy of advanced NLP technologies, we reimagine how to efficiently conduct pan-tumor and detailed trend analyses in solid tumor trials. Don’t miss this session if your CI and strategy teams need augmented data sets beyond the unstructured nature of clinical trial records.

What’s in your competitor’s pipeline? How are their trials progressing? Who is on the cusp of a merger that will increase their funding and how will this impact your business?

The thing is, an infallible single source of truth is not realistic. But how close can we get? In this session, Alex Bour will investigate the elements that would make up a single source of truth. He’ll address key questions that CI professionals need to ask as they embark on their quest and share guidance on what to look for in the answers.
– How do we conduct an effective business analysis of competitors in our space to spot key opportunities and threats?
– How can I find out how well our pipeline/ asset/ portfolio stacks up against the competition and where will the biggest competitive threats come from?
– What’s the most efficient way to stay on top of market events and catalysts, with industry-leading analyst perspective, implications, recommendations?